Detalhe da pesquisa
1.
Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
Mol Cell Proteomics
; 11(7): M111.013243, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22442257
2.
Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.
Biochem Biophys Res Commun
; 425(4): 711-6, 2012 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22842455
3.
Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
J Pharmacol Exp Ther
; 343(1): 178-83, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22787117
4.
Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Cancer Sci
; 102(3): 614-21, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21205082
5.
YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Anticancer Drugs
; 22(5): 454-62, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21389848
6.
Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
Drug Metab Dispos
; 37(3): 619-28, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19056913
7.
Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
Clin Cancer Res
; 14(20): 6496-504, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18927289
8.
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Cancer Res
; 67(17): 8014-21, 2007 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17804712
9.
Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.
Nucl Med Biol
; 40(2): 221-6, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23141550
10.
Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.
Int J Biochem Mol Biol
; 3(2): 179-97, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22773958
11.
Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Leuk Res
; 35(6): 787-92, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21237508
12.
YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Int J Oncol
; 39(3): 569-75, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21674125
13.
Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Clin Cancer Res
; 17(16): 5423-31, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21737502
14.
[Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155].
Nihon Yakurigaku Zasshi
; 136(4): 198-203, 2010 Oct.
Artigo
em Japonês
| MEDLINE | ID: mdl-20948154
15.
Telomerase is upregulated in irreversible preneoplastic lesions during bladder carcinogenesis in rats.
Jpn J Cancer Res
; 93(5): 495-500, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12036444